We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Long-Short Technology Trakrs Index (Cash Component) | DOWI:CYX | Dow Jones Indices | Index |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0 | - |
Cytomyx Holdings PLC 04 August 2005 For Immediate Release 4 August 2005 Cytomyx further expands ion channel cell line capabilities with a worldwide co-exclusive license agreement with Wyeth Pharmaceuticals Validated Ion Channel cell lines for Kv4.3 and the four KChIP accessory sub-unit proteins are now available from Cytomyx Cytomyx Ltd (Cambridge, UK), a division of Cytomyx Holdings, PLC (AIM:CYX.L), a leading provider of drug discovery products and services, is pleased to announce that it has signed a worldwide co-exclusive license agreement with Wyeth Pharmaceuticals (PA, USA) which allows Cytomyx to create and market cell lines expressing the ion channel, Kv4.3 , and the four KChIP accessory sub-units as research reagents for use in drug discovery and safety pharmacology screening. Wyeth holds the patents and patent applications relating to the ion channels Kv4.3, and the four KChIP accessory sub-units. The validated cell lines can also be accessed via Cytomyx' unique IonScreenTM, Ion Channel Screening Service. The service combines Cytomyx' unparalleled range of validated ion channel cell lines with its expertise in automated electrophysiology to deliver timely, high quality data. This strategically important agreement expands further the unique ion channel cell line and screening service portfolio offered by Cytomyx to pharmaceutical and biotechnology clients worldwide. Currently the company has 18 validated ion channel cell lines available and 50 more are in development. Cytomyx continues to be the industry leader for ion channel related products and services and has seven out of the top ten pharmaceutical companies as clients to date. Kv4.3 and the four KChiP accessory sub-units are important targets for drug discovery and safety pharmacology because they combine in different ways in different tissues to make a significant contribution to regulating the electrical activity of the brain and the heart. This regulation can be disturbed by diseases, is at the core of learning and memory and can be the cause of the side effects of medicines. In consideration of the license Wyeth Pharmaceuticals will access know-how and validated cell lines from Cytomyx, enabling them to progress internal drug screening and safety pharmacology programs. -Ends- For Further Information Contact: Cytomyx Tel: +44 (0) 1223 508191 6-7 Technopark, Cambridge, CB5 8PB, UK. Fax: +44 (0) 1223 508198 Mike Kerins, CEO, Email: mike.kerins@cytomyx.com Web: www.cytomyx.com Wyeth Pharmaceuticals, Tel: +1 484 865 8947 500 Arcola Road, Collegeville, PA, 19426, USA Fax: +1 484 865 9301 Christine Foster, Senior Director, Licensing, Email: fosterc1@wyeth.com Web: www.Wyeth.com Buchanan Communications Tel: +44 (0)207 466 500 107 Cheapside, London EC2V 6DN Fax: +44 (0)207 466 5001 Mark Court, Director Mary-Jane Johnson, Account Director Note to Editors About Cytomyx Holdings Cytomyx Holdings plc is a rapidly growing life science company based in Cambridge, UK. The Company's primary focus is on developing novel technologies that assist pharmaceutical and biotechnology companies in their efforts to develop new treatments more effectively. The company does this by providing solutions that provide early insights into the likely efficacy and safety profile of new drugs in development. The Company has two main areas of expertise: the use of human clinical samples in understanding the linkage between gene expression and disease and the development of cell-based assays that are used to support ion channel drug discovery and predict potential cardiac toxicity in new drugs. Cytomyx is listed on the AIM market of the London Stock Exchange (CYX.L). For more information visit www.cytomyx-holdings.com This information is provided by RNS The company news service from the London Stock Exchange END NRABLGDICUGGGUX
1 Year Long-Short Technology Trakrs Index (Cash Component) Chart |
1 Month Long-Short Technology Trakrs Index (Cash Component) Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions